129 168

Cited 77 times in

Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis

Authors
 S. T. Choi  ;  J. H. Kim  ;  E.-J. Kang  ;  S.-W. Lee  ;  M.-C. Park  ;  Y.-B. Park  ;  S.-K. Lee 
Citation
 RHEUMATOLOGY , Vol.47(12) : 1775-1779, 2008 
Journal Title
 RHEUMATOLOGY 
ISSN
 0080-2727 
Issue Date
2008
MeSH
Adult ; Antibodies, Monoclonal/therapeutic use ; Antirheumatic Agents/therapeutic use ; Biomarkers/blood ; Bone Remodeling* ; Cross-Sectional Studies ; Cytokines/blood ; Cytokines/genetics ; Etanercept ; Female ; Gene Expression ; Humans ; Immunoglobulin G/therapeutic use ; Infliximab ; Interleukin-6/blood ; Male ; Middle Aged ; Osteopontin/blood ; Osteopontin/genetics ; Osteopontin/physiology* ; RNA, Messenger/genetics ; Receptors, Tumor Necrosis Factor/therapeutic use ; Reverse Transcriptase Polymerase Chain Reaction/methods ; Severity of Illness Index ; Spondylitis, Ankylosing/blood ; Spondylitis, Ankylosing/drug therapy ; Spondylitis, Ankylosing/physiopathology* ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/blood ; Young Adult
Keywords
Osteopontin ; Ankylosing spondylitis ; Bone remodelling ; Disease activity
Abstract
OBJECTIVES: To determine whether osteopontin (OPN) is increased in patients with AS and to investigate its relationship to inflammatory disease activity and bone remodelling process. METHODS: This cross-sectional study included 30 patients with AS and 23 age- and sex-matched healthy controls. We assessed clinical characteristics and laboratory parameters including the ESR, CRP, lipid profiles, the Bath AS disease activity index (BASDAI) and the Bath AS radiographic index (BASRI). To evaluate bone metabolism, we tested ALP, OCN and C-telopeptide of type I collagen (CTX-I). Plasma levels of OPN, TNF-alpha and IL-6 were measured by ELISA, and mRNA expression in peripheral blood mononuclear cells (PBMCs) was performed by RT-PCR. Changes in OPN level were also evaluated in eight patients after the treatment with a TNF-alpha blocker. RESULTS: Patients with AS had significantly higher plasma OPN, TNF-alpha and IL-6 levels and more mRNA expression than healthy controls. Plasma OPN levels were correlated with serum ALP, OCN and CTX-I levels, but not with ESR, CRP, lipid profiles, BASDAI or BASRI. Treatment with a TNF-alpha blocker did not alter OPN levels, although it reduced the disease activity. CONCLUSIONS: Patients with AS had higher levels of OPN compared with controls. The plasma OPN level was correlated with serum ALP, OCN and CTX-I levels, but not with disease activity in AS. OPN might be involved in bone remodelling rather than in inflammation in AS.
Files in This Item:
T200805239.pdf Download
DOI
10.1093/rheumatology/ken385
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Jin(강은진)
Park, Min Chan(박민찬) ORCID logo https://orcid.org/0000-0003-1189-7637
Park, Yong Beom(박용범)
Lee, Sang Won(이상원) ORCID logo https://orcid.org/0000-0002-8038-3341
Lee, Soo Kon(이수곤)
Choi, Sang Tae(최상태)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/108355
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse